Relative contribution of VKORC1, CYP2C9, and INR response to warfarin stable dose

被引：15
|
作者：
Suarez-Kurtz, Guilherme [1 ]
Perini, Jamila A. [1 ]
Silva-Assuncao, Edimilson [1 ]
Struchiner, Claudio J. [1 ]
机构：
[1] Inst Nacl Canc, Div Farmacol, BR-21230050 Rio De Janeiro, Brazil
来源：
BLOOD | 2009年 / 113卷 / 17期
关键词：
POLYMORPHISMS; REQUIREMENTS;
D O I：
10.1182/blood-2009-01-200600
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4125 / 4126
页数：2
相关论文
共 50 条
  • [31] Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients
    Sripriya Natarajan
    Chandrashekhar K. Ponde
    Rajesh M. Rajani
    Farah Jijina
    Roopkumar Gursahani
    Pradnya P. Dhairyawan
    Tester F. Ashavaid
    Pharmacological Reports, 2013, 65 : 1375 - 1382
  • [32] Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients
    Natarajan, Sripriya
    Ponde, Chandrashekhar K.
    Rajani, Rajesh M.
    Jijina, Farah
    Gursahani, Roopkumar
    Dhairyawan, Pradnya P.
    Ashavaid, Tester F.
    PHARMACOLOGICAL REPORTS, 2013, 65 (05) : 1375 - 1382
  • [33] Polymorphism of the CYP2C9 and VKORC1 genes: a comment RESPONSE
    Colet, Christiane de Fatima
    JORNAL VASCULAR BRASILEIRO, 2021, 20
  • [34] Algorithms using clinical and genetic data (CYP2C9, VKORC1) are relevant to predict warfarin dose in patients with different INR targets
    Le Cam-Duchez, Veronique
    Fretigny, Mathilde
    Cailleux, Nicole
    Gandelin, Catherine
    Levesque, Herve
    Borg, Jeanne-Yvonne
    THROMBOSIS RESEARCH, 2010, 126 (03) : E235 - E237
  • [35] A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional
    Sridharan, Kannan
    Sivaramakrishnan, Gowri
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (03) : 640 - 648
  • [36] Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population
    Jia, LiQun
    Wang, Zanxin
    Men, Jianlong
    Cai, Heng
    Wei, Minxin
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 13 : 421 - 425
  • [37] Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin
    Fung, Erik
    Patsopoulos, Nikolaos A.
    Belknap, Steven M.
    O'Rourke, Daniel J.
    Robb, John F.
    Anderson, Jeffrey L.
    Shworak, Nicholas W.
    Moore, Jason H.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2012, 38 (08): : 893 - 904
  • [38] Frequency of CYP2C9 and VKORC1 Gene Polymorphisms and Their Influence on Warfarin Dose in Egyptian Pediatric Patients
    Mennat-Allah Kamal El-Din
    Marwa Salah Farhan
    Randa Ibrahim El Shiha
    Rania Mohammed Helmy El-Kaffas
    Somaia Mohammed Mousa
    Pediatric Drugs, 2014, 16 : 337 - 341
  • [39] Frequency of CYP2C9 and VKORC1 Gene Polymorphisms and Their Influence on Warfarin Dose in Egyptian Pediatric Patients
    El-Din, Mennat-Allah Kamal
    Farhan, Marwa Salah
    El Shiha, Randa Ibrahim
    El-Kaffas, Rania Mohammed Helmy
    Mousa, Somaia Mohammed
    PEDIATRIC DRUGS, 2014, 16 (04) : 337 - 341
  • [40] Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy
    Ferder, N. S.
    Eby, C. S.
    Deych, E.
    Harris, J. K.
    Ridker, P. M.
    Milligan, P. E.
    Goldhaber, S. Z.
    King, C. R.
    Giri, T.
    McLeod, H. L.
    Glynn, R. J.
    Gage, B. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (01) : 95 - 100
12345